Nordic Life Science 1
TOP STORIES BUSINESS Agnete B Fredriksen, Preside
nt and CSO, and Michael Engsig, CEO, Vaccibody is an ideal partner for us. They are dedicated to the marketing and distribution of novel, laboratory-based assays and are active in 25 markets, directly serving 15 European and Asia Pacific countries. They will help us meet strong interest for qDBS across the wide range of both existing and new applications such as therapeutic drug monitoring, and the genomics anti-doping testing we had originally identified. In addition, we are working with several groups involved in COVID-19 testing and plan to launch antibody testing in Sweden together with several health care regions,” says Christopher Aulin, CEO, Capitainer. Under the terms of an exclusive worldwide license and collaboration agreement with Genentech, Vaccibody will receive USD 200 million in initial upfront and near-term payments. companies will progress Vaccibody’s investigational product, VB10.NEO, an individualized DNAbased neoantigen vaccine for the treatment of cancers, into clinical trials. In addition to the initial upfront and near-term payments, Vaccibody will be eligible to receive up to a further USD 515 million in potential payments and milestones, plus low double-digit tiered royalties on sales of commercialized products arising from the partnership. 12 Following completion of the Phase 1b study, Genentech will have responsibility and bear all costs for clinical, regulatory, manufacturing and commercialization activities. The payments and milestones received under the agreement will enable Vaccibody to accelerate and expand its other internal R&D programs. Vaccibody will focus on advancing and expanding its pipeline of product candidates in the areas of oncology e.g., shared antigen cancer vaccines and infectious diseases. Vaccibody is also listed on the Norwegian trading platform Merkur Market, owned and operated by the Oslo Stock Exchange. NORDICLIFESCIENCE.ORG PHOTO TOMMI PARKKONEN